Targeted Therapy Recommendations for Therapy Refractory Solid Tumors—Data from the Real-World Precision Medicine Platform MONDTI
Advanced therapy-refractory solid tumors bear a dismal prognosis and constitute a major challenge in offering effective treatment strategies. In this real-world retrospective analysis of our precision medicine platform MONDTI, we describe the molecular profile of 554 patients diagnosed with 17 diffe...
Main Authors: | Hossein Taghizadeh, Matthias Unseld, Martina Spalt, Robert M. Mader, Leonhard Müllauer, Thorsten Fuereder, Markus Raderer, Maria Sibilia, Mir Alireza Hoda, Stefanie Aust, Stephan Polterauer, Wolfgang Lamm, Rupert Bartsch, Matthias Preusser, Kautzky-Willer A., Gerald W. Prager |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Journal of Personalized Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2075-4426/10/4/188 |
Similar Items
-
Outcome of Targeted Therapy Recommendations for Metastatic and Recurrent Head and Neck Cancers
by: Hossein Taghizadeh, et al.
Published: (2020-11-01) -
Precision Medicine for the Management of Therapy Refractory Colorectal Cancer
by: Hossein Taghizadeh, et al.
Published: (2020-12-01) -
Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI
by: Christoph C Zielinski, et al.
Published: (2019-07-01) -
Gender differences in molecular‐guided therapy recommendations for metastatic malignant mesothelioma
by: Hossein Taghizadeh, et al.
Published: (2020-07-01) -
Application of mTORC1 Inhibitors for Tissue-Agnostic Management of Standard-Therapy-Refractory Solid Tumors
by: Mader, R.M, et al.
Published: (2022)